EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC 3.0

Interpreting Gastrointestinal Recovery After Tegileridine-Based PCIA in Elderly Colorectal Surgery Patients [Letter]

Chenjie Qiu

Drug Design, Development and Therapy · 2026-07 · Volume 20 · 1-3

DOI: 10.2147/dddt.s643337 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Drug Design, Development and Therapy, 2026-07. Verfasst von Chenjie Qiu. Beteiligte Einrichtung: Department of General Surgery, Changzhou Hospital of Traditional Chinese Medicine, Changzhou, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We read with great interest the randomized trial by He et al comparing tegileridine-based with sufentanil-based patientcontrolled intravenous analgesia (PCIA) for gastrointestinal recovery in elderly patients undergoing laparoscopic colorectal cancer surgery. 1 The authors should be commended for addressing a clinically relevant question within an enhanced recovery framework, particularly because opioid-related gastrointestinal dysfunction remains a major barrier to recovery after colorectal surgery.[2][3][4] Nevertheless, several methodological and interpretative issues deserve careful consideration before tegileridine-based PCIA is adopted as a safer or gastrointestinal-protective strategy in this population.First, the clinical meaning of the primary endpoint is uncertain.The adjusted between-group difference in I-FEED score on postoperative day 3 was statistically significant but modest, at -0.72 points.The I-FEED score has preliminary validity evidence in colorectal surgery, 5 but a generally accepted minimal clinically important difference has not been established.Moreover, the reported difference in time to first flatus was only 4 hours, and time to first defecation did not differ significantly.These findings suggest that the observed effect may represent earlier symptom improvement rather than a clearly meaningful acceleration of bowel recovery.Component-level I-FEED data would be particularly useful, because nausea and emesis are components of I-FEED and were also counted as postoperative adverse events.Without showing whether intake, abdominal examination, and duration of symptoms improved independently of nausea/vomiting, it is difficult to separate true gastrointestinal motility recovery from a reduction in opioid-related PONV.Second, the choice of the per-protocol set as the primary analysis may have introduced selection bias.Fourteen randomized patients were excluded, including patients with conversion to open surgery, operative time exceeding 4 hours, postoperative ICU transfer, and early discontinuation of the analgesia pump.These are not random inconveniences; they are clinically related to surgical stress, opioid exposure, complications, and delayed gastrointestinal recovery.CONSORT principles favor preserving randomization through intention-to-treat analyses wherever possible.6 A full treatment-policy estimand, multipleimputation analysis, or worst-case sensitivity analysis would better clarify whether the results are robust in the population clinicians actually treat.Third, the comparison was not equianalgesic.The authors transparently acknowledge that no validated conversion ratio exists between tegileridine and sufentanil.However, this limitation is central to causal interpretation.Similar NRS scores and PCIA press counts do not prove comparable opioid exposure, especially when background infusions, early discontinuation, rescue antiemetics, and drug-specific pharmacokinetics may differ.Reporting total delivered study drug, PCIA duration, unsuccessful demands, sedation scores, antiemetic rescue timing, and ideally exposure-response analyses would help distinguish a pharmacologic gastrointestinal advantage from a lower effective opioid burden.This is important because postoperative opioid dose itself has been associated with prolonged ileus after laparoscopic colorectal surgery.4

Autor:innen und Institutionen

  • Department of General Surgery, Changzhou Hospital of Traditional Chinese Medicine, Changzhou, People's Republic of China.

Zitieren

APA

Qiu, C. (2026). Interpreting Gastrointestinal Recovery After Tegileridine-Based PCIA in Elderly Colorectal Surgery Patients [Letter]. Drug Design, Development and Therapy, Volume 20, 1-3. https://doi.org/10.2147/dddt.s643337

Vancouver

Qiu C. Interpreting Gastrointestinal Recovery After Tegileridine-Based PCIA in Elderly Colorectal Surgery Patients [Letter]. Drug Design, Development and Therapy. 2026;Volume 20:1-3. doi:10.2147/dddt.s643337

BibTeX
@article{Qiu2026,
  author = {Qiu, Chenjie},
  title = {Interpreting Gastrointestinal Recovery After Tegileridine-Based PCIA in Elderly Colorectal Surgery Patients [Letter]},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--3},
  doi = {10.2147/dddt.s643337}
}
Kostenlos starten →